Cerebrospinal fluid proteomics define the natural history of autosomal dominant Alzheimer's disease
Nenhuma Miniatura disponível
Citações na Scopus
10
Tipo de produção
article
Data de publicação
2023
Título da Revista
ISSN da Revista
Título do Volume
Editora
NATURE PORTFOLIO
Autores
JOHNSON, Erik C. B.
BIAN, Shijia
HAQUE, Rafi U.
CARTER, E. Kathleen
WATSON, Caroline M.
GORDON, Brian A.
PING, Lingyan
DUONG, Duc M.
EPSTEIN, Michael P.
MCDADE, Eric
Citação
NATURE MEDICINE, v.29, n.8, p.1979-+, 2023
Resumo
Alzheimer's disease (AD) pathology develops many years before the onset of cognitive symptoms. Two pathological processes-aggregation of the amyloid-& beta; (A & beta;) peptide into plaques and the microtubule protein tau into neurofibrillary tangles (NFTs)-are hallmarks of the disease. However, other pathological brain processes are thought to be key disease mediators of A & beta; plaque and NFT pathology. How these additional pathologies evolve over the course of the disease is currently unknown. Here we show that proteomic measurements in autosomal dominant AD cerebrospinal fluid (CSF) linked to brain protein coexpression can be used to characterize the evolution of AD pathology over a timescale spanning six decades. SMOC1 and SPON1 proteins associated with A & beta; plaques were elevated in AD CSF nearly 30 years before the onset of symptoms, followed by changes in synaptic proteins, metabolic proteins, axonal proteins, inflammatory proteins and finally decreases in neurosecretory proteins. The proteome discriminated mutation carriers from noncarriers before symptom onset as well or better than A & beta; and tau measures. Our results highlight the multifaceted landscape of AD pathophysiology and its temporal evolution. Such knowledge will be critical for developing precision therapeutic interventions and biomarkers for AD beyond those associated with A & beta; and tau. Proteomic analysis of cerebrospinal fluid from individuals with autosomal dominant Alzheimer's disease reveals how this complex and chronic disease evolves over many decades.
Palavras-chave
Referências
- Arboleda-Velasquez JF, 2019, NAT MED, V25, P1680, DOI 10.1038/s41591-019-0611-3
- Bai B, 2020, NEURON, V105, P975, DOI 10.1016/j.neuron.2019.12.015
- Bandos AI, 2005, STAT MED, V24, P2873, DOI 10.1002/sim.2149
- Barthelemy NR, 2020, NAT MED, V26, P398, DOI 10.1038/s41591-020-0781-z
- Bateman RJ, 2012, NEW ENGL J MED, V367, P795, DOI 10.1056/NEJMoa1202753
- Bateman RJ, 2011, ALZHEIMERS RES THER, V3, DOI 10.1186/alzrt59
- Boerwinkle AH, 2021, NEUROLOGY, V97, pE76, DOI 10.1212/WNL.0000000000012123
- Bridel C, 2019, JAMA NEUROL, V76, P1035, DOI 10.1001/jamaneurol.2019.1534
- Buchhave P, 2012, ARCH GEN PSYCHIAT, V69, P98, DOI 10.1001/archgenpsychiatry.2011.155
- Bürkner PC, 2018, R J, V10, P395
- Bürkner PC, 2017, J STAT SOFTW, V80, P1, DOI 10.18637/jss.v080.i01
- Campbell MR, 2021, ALZH DEMENT-DADM, V13, DOI 10.1002/dad2.12190
- Cantor H, 2009, NAT REV IMMUNOL, V9, P137, DOI 10.1038/nri2460
- Carr SA, 2014, MOL CELL PROTEOMICS, V13, P907, DOI 10.1074/mcp.M113.036095
- Chen WL, 2015, REV NEUROSCIENCE, V26, P129, DOI 10.1515/revneuro-2014-0051
- Connolly K, 2023, ALZHEIMERS DEMENT, V19, P9, DOI 10.1002/alz.12612
- Craig-Schapiro R, 2010, BIOL PSYCHIAT, V68, P903, DOI 10.1016/j.biopsych.2010.08.025
- Dammer EB, 2022, ALZHEIMERS RES THER, V14, DOI 10.1186/s13195-022-01113-5
- Dayon L, 2018, ALZHEIMERS RES THER, V10, DOI 10.1186/s13195-018-0397-4
- Dopico-López A, 2021, TRANSL RES, V230, P68, DOI 10.1016/j.trsl.2020.10.004
- Esteve P, 2019, NAT NEUROSCI, V22, P1258, DOI 10.1038/s41593-019-0432-1
- Fagan AM, 2009, EMBO MOL MED, V1, P371, DOI 10.1002/emmm.200900048
- Fan JS, 2018, NEUROPSYCH DIS TREAT, V14, P495, DOI 10.2147/NDT.S157099
- Fernandez S, 2021, J ALZHEIMERS DIS REP, V5, P111, DOI 10.3233/ADR-200246
- FOLSTEIN MF, 1975, J PSYCHIAT RES, V12, P189, DOI 10.1016/0022-3956(75)90026-6
- Gillette MA, 2013, NAT METHODS, V10, P28, DOI 10.1038/nmeth.2309
- Gordon BA, 2018, LANCET NEUROL, V17, P241, DOI 10.1016/S1474-4422(18)30028-0
- Higginbotham L, 2020, SCI ADV, V6, DOI 10.1126/sciadv.aaz9360
- Hondius DC, 2018, ACTA NEUROPATHOL COM, V6, DOI 10.1186/s40478-018-0540-2
- Hynes R. O., 2012, Cold Spring Harb Perspect Biol., V4, pa004903, DOI [DOI 10.1101/CSHPERSPECT.A004903, 10.1101/cshperspect.a004903]
- Jack CR, 2018, ALZHEIMERS DEMENT, V14, P535, DOI 10.1016/j.jalz.2018.02.018
- Janelidze S, 2016, ANN CLIN TRANSL NEUR, V3, P154, DOI 10.1002/acn3.274
- Johnson ECB, 2022, NAT NEUROSCI, V25, P213, DOI 10.1038/s41593-021-00999-y
- Johnson ECB, 2020, NAT MED, V26, P769, DOI 10.1038/s41591-020-0815-6
- Karch Celeste M, 2015, Biol Psychiatry, V77, P43, DOI 10.1016/j.biopsych.2014.05.006
- Karikari TK, 2021, MOL PSYCHIATR, V26, P429, DOI 10.1038/s41380-020-00923-z
- KLAR A, 1992, CELL, V69, P95, DOI 10.1016/0092-8674(92)90121-R
- Kremer DM, 2021, NAT COMMUN, V12, DOI 10.1038/s41467-021-24859-2
- Leuzy A, 2022, EMBO MOL MED, V14, DOI 10.15252/emmm.202114408
- Li Y, 2022, NEUROLOGY, V98, pE688, DOI 10.1212/WNL.0000000000013211
- Magistretti PJ, 2015, NEURON, V86, P883, DOI 10.1016/j.neuron.2015.03.035
- Mawuenyega KG, 2010, SCIENCE, V330, P1774, DOI 10.1126/science.1197623
- McKay NS, 2023, NAT NEUROSCI, V26, P1449, DOI 10.1038/s41593-023-01359-8
- Morenas-Rodríguez E, 2022, LANCET NEUROL, V21, P329, DOI 10.1016/S1474-4422(22)00027-8
- MORRIS JC, 1993, NEUROLOGY, V43, P2412, DOI 10.1212/WNL.43.11.2412-a
- Morris JC, 2022, BRAIN, V145, P3594, DOI 10.1093/brain/awac181
- Neff RA, 2021, SCI ADV, V7, DOI 10.1126/sciadv.abb5398
- Nelson PT, 2019, BRAIN, V142, P1503, DOI 10.1093/brain/awz099
- Newington JT, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0019191
- Nichols E., 2022, LANCET PUBLIC HEALTH, V7, pe105, DOI [DOI 10.1016/S2468-2667(21)00249-8, 10.1016/S2468-2667(21)00249-8]
- Ossenkoppele R, 2022, LANCET NEUROL, V21, P726, DOI 10.1016/S1474-4422(22)00168-5
- Potter R, 2013, SCI TRANSL MED, V5, DOI 10.1126/scitranslmed.3005615
- Preische O, 2019, NAT MED, V25, P277, DOI 10.1038/s41591-018-0304-3
- Rajkumar K, 2016, CELL BIOCHEM FUNCT, V34, P394, DOI 10.1002/cbf.3198
- Raulin AC, 2022, MOL NEURODEGENER, V17, DOI 10.1186/s13024-022-00574-4
- Reiman EM, 2020, NAT COMMUN, V11, DOI 10.1038/s41467-019-14279-8
- Ringman JM, 2016, J NEUROPATH EXP NEUR, V75, P284, DOI 10.1093/jnen/nlv028
- Rosmus DD, 2022, BIOMEDICINES, V10, DOI 10.3390/biomedicines10040840
- Rother C, 2022, NAT COMMUN, V13, DOI 10.1038/s41467-022-34538-5
- Ryman Davis C, 2014, Neurology, V83, P253, DOI 10.1212/WNL.0000000000000596
- Salvadó G, 2022, EUR J NUCL MED MOL I, V49, P4567, DOI 10.1007/s00259-022-05897-4
- Schultz SA, 2020, NEUROBIOL DIS, V142, DOI 10.1016/j.nbd.2020.104960
- Sherva Richard, 2014, Alzheimers Dement, V10, P45, DOI 10.1016/j.jalz.2013.01.008
- Shippy DC, 2020, FRONT CELL NEUROSCI, V14, DOI 10.3389/fncel.2020.563446
- Spellman DS, 2015, PROTEOM CLIN APPL, V9, P715, DOI 10.1002/prca.201400178
- Strain JF, 2022, NEUROBIOL DIS, V168, DOI 10.1016/j.nbd.2022.105714
- Suárez-Calvet M, 2020, EMBO MOL MED, V12, DOI 10.15252/emmm.202012921
- Suárez-Calvet M, 2018, EMBO MOL MED, V10, DOI [10.15252/emmm.2018097121, 10.15252/emmm.201809712]
- Tchaikovski V, 2008, ARTERIOSCL THROM VAS, V28, P322, DOI 10.1161/ATVBAHA.107.158022
- Townley RA, 2018, NEUROLOGY, V90, P118, DOI 10.1212/WNL.0000000000004840
- Ulland TK, 2017, CELL, V170, P649, DOI 10.1016/j.cell.2017.07.023
- Wan YW, 2020, CELL REP, V32, DOI 10.1016/j.celrep.2020.107908
- Watson CM, 2023, SCI DATA, V10, DOI 10.1038/s41597-023-02158-3
- Wisniewski T, 1996, NEUROREPORT, V7, P667, DOI 10.1097/00001756-199601310-00068
- Xiang XY, 2021, SCI TRANSL MED, V13, DOI 10.1126/scitranslmed.abe5640
- Zhou MT, 2020, CLIN PROTEOM, V17, DOI 10.1186/s12014-020-09285-8